Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Eli Lilly and Company
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Key Projects == Eli Lilly is involved with a highly diversified product range in pharmaceuticals, offering solutions for various medical conditions and collaborating with a large number of companies as summarised below. Details are in the following section. '''Overview of all products offered by Eli Lilly''' <u>Diabetes Medications</u> * Basaglar * Humalog U-100, U-200 * Humalog Mix 75/25, Mix 50/50 * Insulin lispro, lispro protamine, lispro mix 75/25 * Humulin * Humulin 70/30, N, R, U-500 * Jardiance, Trajenta, Trulicity for type 2 diabetes. <u>Cancer Treatments</u> * Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. * Cyramza for various cancer types including metastatic gastric cancer, NSCLC, and hepatocellular carcinoma. * Erbitux for colorectal cancers and head and neck cancers. * Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer. * Tyvyt for classic Hodgkin's lymph and non-squamous NSCLC. * Verzenio for metastatic breast cancer and early breast cancer. <u>Other Medical Conditions (Rheumatological, Dermatological, Psychiatric & Urologic)</u> * Olumiant for rheumatoid arthritis. * Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and axial spondylarthritis. * Cymbalta for depressive disorder, anxiety, fibromyalgia, and chronic pain. * Emgality for migraine prevention and cluster headache. * Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. * Cialis for erectile dysfunction and benign prostatic hyperplasia. * Forteo for osteoporosis. <u>COVID-19 Medications</u> * Bamlanivimab and etesevimab. * Bebtelovimab. <u>Collaborations</u> The company collaborates with various organizations including: * Incyte Corporation * Boehringer Ingelheim Pharmaceuticals, Inc. * AbCellera Biologics Inc. * Junshi Biosciences * Regor Therapeutics Group * Lycia Therapeutics, Inc. * Kumquat Biosciences Inc. * Entos Pharmaceuticals Inc. * Foghorn Therapeutics Inc. '''Most successful products''' * Trulicity (dulaglutide) is a once-weekly injectable GLP-1 receptor agonist that is being developed for the treatment of type 2 diabetes. The drug was approved by the FDA in 2014 and is currently the top-selling diabetes drug in the world. ** Trulicity (dulaglutide) has generated $6.9 billion in sales overall since 2014. * Verzenio (abemaciclib) is an oral CDK4/6 inhibitor that is being developed for the treatment of breast cancer. The drug was approved by the FDA in 2017. ** Verzenio (abemaciclib) has generated $7.4 billion in sales overall since 2017. * Humalog (insulin lispro) is a fast-acting insulin analog that is being developed for the treatment of diabetes. The drug was approved by the FDA in 1996 and is currently the most widely used insulin analog in the world. * Cymbalta (duloxetine) is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that is being developed for the treatment of depression, anxiety, and chronic pain. The drug was approved by the FDA in 2004. * Prozac (fluoxetine) is a selective serotonin reuptake inhibitor (SSRI) that is being developed for the treatment of depression. The drug was approved by the FDA in 1986 and is currently the most widely prescribed antidepressant in the world. ** Prozac (Fluoxetine) has generated ~$21 billion for Eli Lilly since it was approved. It continues to be a source of revenue since the expiration of its patent in 2001. * Mounjaro (tirzepatide) is a once-weekly injectable medication that is used to treat type 2 diabetes. Tirzepatide was approved by the U.S. Food and Drug Administration (FDA) in 2022. It is the first dual GLP-1 and GIP receptor agonist to be approved for the treatment of type 2 diabetes. It has also shown to be very effective in weight loss. ** Tirzepatide has generated $4.8 billion in sales since its approval in 2022, and is one of Eli Lilly's most promising drugs for future revenue. Many of these products are in the top 10 best-selling drugs in the world. They are all innovative medicines that address unmet medical needs. They are also all relatively new drugs, which means that they have the potential to generate even more revenue in the years to come. Eli Lilly is a research-intensive pharmaceutical company with a strong track record of innovation. The company has a number of promising projects in development, and it is well-positioned to continue growing in the years to come. '''Future project collaboration details''' Incyte Corporation: Eli Lilly and Incyte Corporation are collaborating on the development of new cancer drugs. The companies are currently developing a combination therapy of baricitinib and pembrolizumab for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Boehringer Ingelheim Pharmaceuticals, Inc.: Eli Lilly and Boehringer Ingelheim Pharmaceuticals, Inc. are collaborating on the development of new diabetes drugs. The companies are currently developing a once-weekly injectable GLP-1 receptor agonist called tirzepatide. AbCellera Biologics Inc.: Eli Lilly and AbCellera Biologics Inc. are collaborating on the development of new antibody-based treatments for COVID-19. The companies are currently developing a combination therapy of bamlanivimab and etesevimab. Junshi Biosciences: Eli Lilly and Junshi Biosciences are collaborating on the development of new cancer drugs. The companies are currently developing a combination therapy of fulvestrant and durvalumab for the treatment of breast cancer. Regor Therapeutics Group: Eli Lilly and Regor Therapeutics Group are collaborating on the development of new treatments for Alzheimer's disease. The companies are currently developing a drug called donanemab, which is a monoclonal antibody that targets amyloid beta plaques. Lycia Therapeutics, Inc.: Eli Lilly and Lycia Therapeutics, Inc. are collaborating on the development of new treatments for atopic dermatitis. The companies are currently developing a drug called lebrikizumab, which is an anti-IL-13 monoclonal antibody. Kumquat Biosciences Inc.: Eli Lilly and Kumquat Biosciences Inc. are collaborating on the development of new treatments for cancer. The companies are currently developing a drug called pirtobrutinib, which is an oral Bruton's tyrosine kinase inhibitor. Entos Pharmaceuticals Inc.: Eli Lilly and Entos Pharmaceuticals Inc. are collaborating on the development of new treatments for rheumatoid arthritis. The companies are currently developing a drug called ozanimod, which is a sphingosine 1-phosphate receptor modulator. Foghorn Therapeutics Inc.: Eli Lilly and Foghorn Therapeutics Inc. are collaborating on the development of new treatments for pain. The companies are currently developing a drug called FV-100, which is a small molecule that targets the NMDA receptor.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)